**Presentation:** Each tablet contains 500mg diloxanide furoate.

**Indication:** For the treatment of acute and chronic intestinal amoebiasis.

**Dosage and administration:** For oral use.

**Adults:** One 500mg tablet three times daily for ten days.

**Elderly:** There is no need for dosage reduction in the elderly.

**Children:** 20 mg/kg bodyweight daily in divided doses for ten days. Diloxanide is not suitable for use in children weighing less than 25 kg.

**Contraindications:** Hypersensitivity to diloxanide furoate.

**Precautions and warnings:** Keep all medicines out of the reach of children.

**Interactions:** No clinically significant drug interactions known.

**Pregnancy and lactation:** Contraindicated in pregnancy and lactation.

**Undesirable effects:** Vomiting, flatulence, pruritus and urticaria may occur.

*(Please refer to the Summary of Product Characteristics for detailed information)*

**Overdose:** Diloxanide tablets are unlikely to constitute a hazard in overdosage. In severe overdosage, early gastric lavage is recommended. There is no specific antidote. Treatment should be symptomatic and supportive.

**Legal category:** POM

**Basic NHS cost:** £93.50 for 30 tablets.

**Marketing Authorisation Number:** PL 20072/0225

**Marketing Authorisation Holder:** Amdipharm Mercury Company Limited (AMCo), 1st Floor, Capital House, 85 King William Street, London, EC4N 7BL.

**Date of preparation:** April 2014

---

**Adverse events should be reported to the local regulatory authority.**

Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)

Adverse events should also be reported to Amdipharm Mercury Medical Information at **08700 70 30 33** or via e-mail to **medicalinformation@amcolimited.com**